Pulmonary arterial pruning is associated with CT-derived bronchiectasis progression in smokers - 23/09/22
Doi : 10.1016/j.rmed.2022.106971
Wojciech R. Dolliver a, Wei Wang b, Pietro Nardelli c, Farbod N. Rahaghi a, Jose L. Orejas a, Diego J. Maselli d, Andrew Yen e, Kendra Young f, Gregory Kinney f, Raul San José Estépar c, Alejandro A. Diaz a, ⁎ 
a Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, USA
b Division of Sleep Medicine and Circadian Disorders, Brigham and Women's Hospital, Boston, USA
c Department of Radiology, Brigham and Women's Hospital, Boston, USA
d Division of Pulmonary Diseases and Critical Care, University of Texas, San Antonio, USA
e Department of Radiology, University of California, San Diego, USA
f Department of Epidemiology, Colorado School of Public Health, University of Colorado, Aurora, USA
∗Corresponding author. Division of Pulmonary and Critical Care Medicine, 75 Francis St, Boston, MA, 02115, USA.Division of Pulmonary and Critical Care Medicine75 Francis StBostonMA02115USA
Abstract |
Loss of small pulmonary arteries measured as the ratio of blood vessel volume in arteries <5 mm2 in cross-section to total arterial blood vessel volume (BV5a/TBVa), with lower values indicating more pruning, was associated with 5-yr progressing CT-derived bronchiectasis in smokers (Odds Ratio (OR) [95% Confidence interval], 1.28 [1.07–1.53] per 5% lower BV5a/TBVa, P = 0.007). Corresponding results in smokers with COPD were: OR 1.45 [1.11–1.89] per 5% lower BV5a/TBVa, P = 0.007. The results support a vascular factor for structural progression of bronchiectasis.
Le texte complet de cet article est disponible en PDF.Highlights |
• | It is known that bronchiectasis presents with a loss of small pulmonary vessels. |
• | In this study, a loss of small pulmonary arteries was associated with structural bronchiectasis progression. |
• | A vascular factor might play a role in structural bronchiectasis progression. |
Plan
© 2022
Elsevier Ltd. Tous droits réservés.
Vol 202
Article 106971- octobre 2022 Retour au numéro
Article précédent
- Pulmonary vascular disease and exercise hemodynamics in chronic liver disease
- Philipp Douschan, Gabor Kovacs, Teresa Sassmann, Vanessa Stadlbauer, Alexander Avian, Vasile Foris, Elisabeth Tatscher, Franziska Durchschein, Florian Rainer, Walter Spindelboeck, Martin Wagner, Daniela Kniepeiss, Gernot Zollner, Gerhard Bachmaier, Peter Fickert, Horst Olschewski, Rudolf E. Stauber
- In response to “who are the 10%? – Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies”
- Meghan E. McGarry, Susanna A. McColley, Jennifer Taylor-Cousar
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?